Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 322.50
Bid: 322.00
Ask: 323.00
Change: -12.00 (-3.59%)
Spread: 1.00 (0.311%)
Open: 329.00
High: 332.50
Low: 321.00
Prev. Close: 334.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Jul 2017 07:15

RNS Number : 2518K
Oxford Biomedica PLC
06 July 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Oxford Biomedica plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

Chase (GA Group) Nominees Limited 187,227,017*

 

HSBC Global Custody Nominee (UK) Limited 42,906,072*

State Street Nominees Limited 8,432,060*

 

*denotes direct interest

 

Chase (GA Group) Nominees Limited 10,620,273

 

Chase Nominees Limited 5,994,501

 

Vidacos Nominees Limited 11,910,298

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

04/07/2017

6. Date on which issuer notified (DD/MM/YYYY):

05/07/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

8.646%

0.265%

8.911%

3,088,726,215

Position of previous notification (if

applicable)

9.213%

0. 265%

9.478%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesGB0006648157

238,565,149

28,525,072

7.723%

0.923%

SUBTOTAL 8. A

267,090,221

8.646%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

8,198,196*

 

DIRECT INTEREST

0.265%

SUBTOTAL 8. B 1

8,198,196

0.265%

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

8.646%

8.911%

Aviva Group Holdings Limited

8.646%

8.911%

Aviva Investors Holdings Limited

8.646%

8.911%

Aviva Investors Global Services Limited

8.646%

8.911%

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

This notification is prompted by a 8% to 7% change at Direct Interest Level (Box 8A&B)

 

Place of completion

Norwich, England

Date of completion

5 July 2017

Contact name:

Tim Watts

Contact telephone number:

01865 783000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUVSNRBNABRAR
Date   Source Headline
5th Oct 20187:00 amRNSDetails of alliance with Orchard Therapeutics
1st Oct 20189:41 amRNSTotal Voting Rights
24th Sep 201812:20 pmRNSDirector/PDMR Shareholding
20th Sep 201810:57 amEQSHardman & Co Research: Oxford BioMedica (OXB): Partnering strategy delivering profitability
13th Sep 20187:00 amRNSOxford BioMedica Interim Results
13th Sep 20187:00 amRNSOxford BioMedica further capacity expansion
3rd Sep 20189:18 amRNSTotal Voting Rights
28th Aug 20187:00 amRNSKymriah® receives European Commission Approval
22nd Aug 201811:58 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSRNS notice of results OXB
14th Aug 20187:15 amEQSHardman & Co Research: Oxford BioMedica (OXB): Risk-sharing in cystic fibrosis gene-therapy
13th Aug 201810:55 amRNSDirector/PDMR Shareholding
13th Aug 201810:48 amRNSDirector/PDMR Shareholding
10th Aug 201811:39 amRNSPDMR Dealings / Market Share Sale
10th Aug 201811:36 amRNSDirector Dealings / Market Share Sale and Purchase
8th Aug 20182:45 pmRNSShare Options and LTIPs Granted
6th Aug 20187:02 amRNSPartnership for Cystic Fibrosis Gene Therapy
1st Aug 20189:53 amRNSTotal Voting Rights
23rd Jul 201812:54 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 201810:25 amRNSDirectorate Change
2nd Jul 20189:47 amRNSTotal Voting Rights
29th Jun 20181:37 pmRNSKymriah receives positive CHMP opinion
25th Jun 20185:19 pmRNSHoldings in Company
22nd Jun 201812:05 pmRNSConfirmation of change of Auditor
22nd Jun 201812:03 pmRNSDirector Dealings / Market Share Purchase
21st Jun 20185:52 pmRNSHoldings in Company
14th Jun 20189:51 amEQSHardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression
6th Jun 20187:00 amRNSOXB and Axovant Sciences Licence Agreement
4th Jun 20186:08 pmRNSDirectorate Change
1st Jun 20189:24 amRNSBlock Listing Return
1st Jun 20189:19 amRNSTotal Voting Rights
30th May 20184:23 pmRNSHoldings in Company
29th May 20181:21 pmRNSResult of General Meeting
29th May 20181:21 pmRNSResult of AGM
23rd May 20181:40 pmRNSDirector Dealings / Market Share Purchase
4th May 20187:00 amRNSProposed Share Capital Consolidation
2nd May 20187:00 amRNSKymriah receives FDA approval for DLBCL
1st May 20189:37 amRNSTotal Voting Rights
26th Apr 20183:33 pmRNSHolding(s) in Company
26th Apr 20187:30 amRNS2017 Annual Report and Accounts & AGM Notification
23rd Apr 201811:46 amRNSDirector Dealings / Market Share Purchase
11th Apr 20182:11 pmRNSDirector Dealings / Market Share Purchase
9th Apr 20185:39 pmRNSDirector/PDMR Shareholding
9th Apr 201810:47 amRNSDirector/PDMR Shareholding
5th Apr 201812:08 pmRNSDirector/PDMR Shareholding
3rd Apr 20189:45 amRNSTotal Voting Rights
22nd Mar 201811:05 amRNSDirector/PDMR Shareholding
20th Mar 20187:15 amRNSHardman & Co Res: Supply to meet demand
15th Mar 20187:01 amRNSBoard Change
15th Mar 20187:01 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.